PDCD1 and non-small cell lung carcinoma: In patients suffering from renal cell carcinoma (RCC), advanced-stage non–small cell lung cancer (NSCLC), or bladder tumor treated with PD-1/PD-L1 blockade, the use of broad-spectrum antibiotics shortly before or after treatment was associated with adverse clinical outcomes (45).